文献速递脑血管病

脑淀粉样血管病与血肿扩大的风险

Cerebral Amyloid Angiopathy and the Risk of Hematoma Expansion.
PubMed 文献 · Ann Neurol · 2022-08-27

在TICH-2试验的脑出血患者中,评估血肿扩大和良好功能结局是否因脑出血类型而异。共纳入2298例有CT资料的患者,其中脑叶CAA-ICH占8.8%。脑叶CAA-ICH与血肿扩大的风险无独立关联,但血肿扩大的动态变化与其他类型脑出血似乎不同。氨甲环酸显著降低血肿扩大风险(校正OR=0.7,95%CI=0.6-1.0,p=0.020),但与脑出血类型的交互作用无统计学意义(pinteraction=0.058)。

要点

  • 脑叶CAA-ICH患者血肿扩大风险未独立增加,但动态变化与其他类型脑出血似乎不同。
  • 氨甲环酸显著降低血肿扩大风险(校正OR=0.7,95%CI=0.6-1.0,p=0.020)。
  • 氨甲环酸与良好功能结局无关联。

核心结论

  • 脑叶CAA-ICH患者血肿扩大风险未独立增加,但与其他类型脑出血相比似乎具有不同的动态变化,预防血肿扩大的治疗时间窗可能更长。

研究设计与样本

  • TICH-2试验中纳入2298例有基线CT的脑出血患者(98.8%;中位年龄71岁,四分位距60-80岁;女性1014例),根据CT简化Edinburgh标准和MRI Boston标准评估脑出血类型。

主要发现

  • 非脑叶脑出血1637例(71.2%),脑叶脑出血661例(28.8%),其中脑叶CAA-ICH 202例(8.8%,173例依据Edinburgh标准,29例依据Boston标准),脑叶非CAA 459例(20.0%)。
  • 脑叶CAA-ICH与发病至随机化时间的交互作用显著(随时间风险增加,pinteraction<0.001),与基线脑出血体积的交互作用显著(风险恒定 regardless of volume,pinteraction<0.001)。
  • 脑出血类型与血肿扩大风险或良好功能结局无关联。
  • 氨甲环酸显著降低血肿扩大风险(校正OR=0.7,95%CI=0.6-1.0,p=0.020),与脑出血类型的交互作用无统计学意义(pinteraction=0.058)。
  • 氨甲环酸与良好功能结局无关联。

关键数值与推荐

  • 脑叶CAA-ICH与时间的交互作用pinteraction<0.001。
  • 脑叶CAA-ICH与基线脑出血体积的交互作用pinteraction<0.001。
  • 氨甲环酸降低血肿扩大风险:校正OR=0.7,95%CI=0.6-1.0,p=0.020。
  • 氨甲环酸与脑出血类型交互作用:pinteraction=0.058。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed whether hematoma expansion (HE) and favorable outcome differ according to type of intracerebral hemorrhage (ICH). METHODS: Among participants with ICH enrolled in the TICH-2 (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) trial, we assessed baseline scans for hematoma location and presence of cerebral amyloid angiopathy (CAA) using computed tomography (CT, simplified Edinburgh criteria) and magnetic resonance imaging (MRI; Boston criteria) and categorized ICH as lobar CAA, lobar non-CAA, and nonlobar. The main outcomes were HE and favorable functional outcome. We constructed multivariate regression models and assessed treatment effects using interaction terms. RESULTS: A total of 2,298 out of 2,325 participants were included with available CT (98.8%; median age = 71 years, interquartile range = 60-80 years; 1,014 female). Additional MRI was available in 219 patients (9.5%). Overall, 1,637 participants (71.2%) had nonlobar ICH; the remaining 661 participants (28.8%) had lobar ICH, of whom 202 patients had lobar CAA-ICH (8.8%, 173 participants according to Edinburgh and 29 participants according to Boston criteria) and 459 did not (lobar non-CAA, 20.0%). For HE, we found a significant interaction of lobar CAA ICH with time from onset to randomization (increasing risk with time, pinteraction < 0.001) and baseline ICH volume (constant risk regardless of volume, pinteraction < 0.001) but no association between type of ICH and risk of HE or favorable outcome. Tranexamic acid significantly reduced the risk of HE (adjusted odds ratio = 0.7, 95% confidence interval = 0.6-1.0, p = 0.020) without statistically significant interaction with type of ICH (pinteraction = 0.058). Tranexamic acid was not associated with favorable outcome. INTERPRETATION: Risk of HE in patients with lobar CAA-ICH was not independently increased but seems to have different dynamics compared to other types of ICH. The time window for treatment of CAA-ICH to prevent HE may be longer. ANN NEUROL 2022;92:921-930.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Seiffge DJ, Polymeris AA, Law ZK, et al. Cerebral Amyloid Angiopathy and the Risk of Hematoma Expansion. Ann Neurol. 2022. PMID: 36054211. doi:10.1002/ana.26481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。